

# Michael R Jacobs

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4423950/michael-r-jacobs-publications-by-citations.pdf>  
**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

92 papers	2,923 citations	30 h-index	51 g-index
97 ext. papers	3,467 ext. citations	6.1 avg, IF	4.94 L-index

#	Paper	IF	Citations
92	The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2003</b> , 52, 229-46	5.1	365
91	Can Ceftazidime-Avibactam and Aztreonam Overcome $\beta$ -Lactam Resistance Conferred by Metallo- $\beta$ -Lactamases in Enterobacteriaceae?. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,	5.9	143
90	Multicenter Clinical and Molecular Epidemiological Analysis of Bacteremia Due to Carbapenem-Resistant Enterobacteriaceae (CRE) in the CRE Epicenter of the United States. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,	5.9	136
89	Detection of septic transfusion reactions to platelet transfusions by active and passive surveillance. <i>Blood</i> , <b>2016</b> , 127, 496-502	2.2	125
88	Relationship between bacterial load, species virulence, and transfusion reaction with transfusion of bacterially contaminated platelets. <i>Clinical Infectious Diseases</i> , <b>2008</b> , 46, 1214-20	11.6	118
87	Surveillance of carbapenem-resistant <i>Klebsiella pneumoniae</i> : tracking molecular epidemiology and outcomes through a regional network. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 4035-41	5.9	100
86	Detection of bacterial contamination in prestorage culture-negative apheresis platelets on day of issue with the Pan Genera Detection test. <i>Transfusion</i> , <b>2011</b> , 51, 2573-82	2.9	91
85	Activity of CP99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci. <i>Journal of Antimicrobial Chemotherapy</i> , <b>1995</b> , 35, 230-2	5.1	88
84	Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using $\beta$ -Lactamase Inhibitors and $\beta$ -Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234. <i>Journal of Medicinal Chemistry</i> , <b>2018</b> , 61, 4067-4086	8.3	77
83	Evolution of surveillance methods for detection of bacterial contamination of platelets in a university hospital, 1991 through 2004. <i>Transfusion</i> , <b>2006</b> , 46, 719-30	2.9	73
82	Changes in serotypes and antimicrobial susceptibility of invasive <i>Streptococcus pneumoniae</i> strains in Cleveland: a quarter century of experience. <i>Journal of Clinical Microbiology</i> , <b>2008</b> , 46, 982-90	9.7	67
81	Adhesion of <i>Staphylococcus epidermidis</i> to biomedical polymers: contributions of surface thermodynamics and hemodynamic shear conditions. <i>Journal of Biomedical Materials Research Part B</i> , <b>1995</b> , 29, 485-93		59
80	ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and with Defined Extended-Spectrum $\beta$ -Lactamases and Carbapenemases. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> , 63,	5.9	57
79	<i>Corynebacterium striatum</i> : a diphtheroid with pathogenic potential. <i>Clinical Infectious Diseases</i> , <b>1993</b> , 17, 21-5	11.6	56
78	Prevalence and significance of methicillin-resistant <i>Staphylococcus aureus</i> in patients with cystic fibrosis. <i>Pediatric Pulmonology</i> , <b>1988</b> , 4, 159-63	3.5	49
77	Genome dynamics of multidrug-resistant <i>Acinetobacter baumannii</i> during infection and treatment. <i>Genome Medicine</i> , <b>2016</b> , 8, 26	14.4	48
76	Topical fluoroquinolones: antimicrobial activity and in vitro corneal epithelial toxicity. <i>Current Eye Research</i> , <b>1991</b> , 10, 557-63	2.9	47

75	Beyond Piperacillin-Tazobactam: Cefepime and AAI101 as a Potent $\beta$ -Lactam- $\beta$ -Lactamase Inhibitor Combination. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> , 63,	5.9	44
74	Rapid Molecular Diagnostics, Antibiotic Treatment Decisions, and Developing Approaches to Inform Empiric Therapy: PRIMERS I and II. <i>Clinical Infectious Diseases</i> , <b>2016</b> , 62, 181-9	11.6	44
73	Macrolide resistance: an increasing concern for treatment failure in children. <i>Pediatric Infectious Disease Journal</i> , <b>2003</b> , 22, S131-8	3.4	44
72	Susceptibility of <i>Streptococcus pneumoniae</i> , <i>Haemophilus influenzae</i> , and <i>Moraxella catarrhalis</i> to 17 oral antimicrobial agents based on pharmacodynamic parameters: 1998-2001 U S Surveillance Study. <i>Clinics in Laboratory Medicine</i> , <b>2004</b> , 24, 503-30	2.1	44
71	Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic <i>Escherichia coli</i> strains expressing selected single $\beta$ -lactamases. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2015</b> , 82, 65-9	2.9	37
70	Avibactam Restores the Susceptibility of Clinical Isolates of <i>Stenotrophomonas maltophilia</i> to Aztreonam. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,	5.9	36
69	In vitro activity of the new quinolone WCK 771 against staphylococci. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2004</b> , 48, 3338-42	5.9	36
68	Enhancement of a culture-based bacterial detection system (eBDS) for platelet products based on measurement of oxygen consumption. <i>Transfusion</i> , <b>2005</b> , 45, 984-93	2.9	36
67	Targeting Multidrug-Resistant spp.: Sulbactam and the Diazabicyclooctenone $\beta$ -Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent. <i>MBio</i> , <b>2019</b> , 10,	7.8	35
66	Serotype distribution and antimicrobial susceptibility of USA <i>Streptococcus pneumoniae</i> isolates collected prior to and post introduction of 13-valent pneumococcal conjugate vaccine. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2014</b> , 80, 19-25	2.9	35
65	Nadifloxacin: a quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771. <i>Expert Opinion on Pharmacotherapy</i> , <b>2006</b> , 7, 1957-66	4	34
64	Monitoring Ceftazidime-Avibactam and Aztreonam Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant <i>Enterobacter</i> sp. Carrying Both <i>Klebsiella pneumoniae</i> Carbapenemase-4 and New Delhi Metallo- $\beta$ -Lactamase-1. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, 1005-1008	11.6	34
63	Fluoroquinolones as chemotherapeutics against mycobacterial infections. <i>Current Pharmaceutical Design</i> , <b>2004</b> , 10, 3213-20	3.3	30
62	Activity of quinolones against mycobacteria. <i>Drugs</i> , <b>1999</b> , 58 Suppl 2, 19-22	12.1	30
61	Multicenter Clinical Evaluation of BacT/Alert Virtuo Blood Culture System. <i>Journal of Clinical Microbiology</i> , <b>2017</b> , 55, 2413-2421	9.7	29
60	<i>Streptococcus pneumoniae</i> : epidemiology and patterns of resistance. <i>The American Journal of Medicine: Supplement</i> , <b>2004</b> , 117 Suppl 3A, 3S-15S		29
59	Extensively drug-resistant <i>Pseudomonas aeruginosa</i> isolates containing blaVIM-2 and elements of <i>Salmonella</i> genomic island 2: a new genetic resistance determinant in Northeast Ohio. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 5929-35	5.9	28
58	Molecular Diversity and Plasmid Analysis of KPC-Producing <i>Escherichia coli</i> . <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 4073-81	5.9	27

57	Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against <i>Pseudomonas aeruginosa</i> : PRIMERS IV. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 68, 1823-1830	11.6	27
56	Nosocomial Outbreak of Extensively Drug-Resistant <i>Acinetobacter baumannii</i> Isolates Containing Carried on a Plasmid. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,	5.9	24
55	Methylfolate Trap Promotes Bacterial Thymineless Death by Sulfa Drugs. <i>PLoS Pathogens</i> , <b>2016</b> , 12, e1005949	10.5	24
54	Transcriptome Remodeling of during Infection and Treatment. <i>MBio</i> , <b>2017</b> , 8,	7.8	23
53	Activity of quinolones against mycobacteria. <i>Drugs</i> , <b>1995</b> , 49 Suppl 2, 67-75	12.1	23
52	Whole-Genome Comparative Analysis of Two Carbapenem-Resistant ST-258 <i>Klebsiella pneumoniae</i> Strains Isolated during a North-Eastern Ohio Outbreak: Differences within the High Heterogeneity Zones. <i>Genome Biology and Evolution</i> , <b>2016</b> , 8, 2036-43	3.9	22
51	Review of current transfusion therapy and blood banking practices. <i>Blood Reviews</i> , <b>2019</b> , 38, 100593	11.1	22
50	Informing Antibiotic Treatment Decisions: Evaluating Rapid Molecular Diagnostics To Identify Susceptibility and Resistance to Carbapenems against <i>Acinetobacter</i> spp. in PRIMERS III. <i>Journal of Clinical Microbiology</i> , <b>2017</b> , 55, 134-144	9.7	22
49	Antimicrobial resistance among pediatric respiratory tract infections: clinical challenges. <i>Seminars in Pediatric Infectious Diseases</i> , <b>2004</b> , 15, 5-20		20
48	Nacubactam Enhances Meropenem Activity against Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Producing KPC. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> , 63,	5.9	19
47	Telithromycin post-antibiotic and post-antibiotic sub-MIC effects for 10 Gram-positive cocci. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2003</b> , 52, 809-12	5.1	19
46	Oral beta-lactams applied to uncomplicated infections of skin and skin structures. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2007</b> , 57, 55S-65S	2.9	18
45	Evaluation of Etest for susceptibility testing of <i>Mycobacterium tuberculosis</i> . <i>Journal of Clinical Microbiology</i> , <b>2000</b> , 38, 3834-6	9.7	18
44	Benefit-risk Evaluation for Diagnostics: A Framework (BED-FRAME). <i>Clinical Infectious Diseases</i> , <b>2016</b> , 63, 812-7	11.6	18
43	: intriguing aerotolerant gut anaerobe with emerging antimicrobial resistance and pathogenic and probiotic roles in human health. <i>Gut Microbes</i> , <b>2021</b> , 13, 1922241	8.8	17
42	Rapid Replacement of <i>Acinetobacter baumannii</i> Strains Accompanied by Changes in Lipooligosaccharide Loci and Resistance Gene Repertoire. <i>MBio</i> , <b>2019</b> , 10,	7.8	16
41	Complete sequence of a bla(KPC)-harboring cointegrate plasmid isolated from <i>Escherichia coli</i> . <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 2956-9	5.9	16
40	Nasopharyngeal carriage of respiratory pathogens in children undergoing pressure equalization tube placement in the era of pneumococcal protein conjugate vaccine use. <i>Laryngoscope</i> , <b>2007</b> , 117, 295-8	3.6	16

39	Community-Acquired Pyelonephritis in Pregnancy Caused by KPC-Producing <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 4375-8	5.9	14
38	Effects of various test media on the activities of 21 antimicrobial agents against <i>Haemophilus influenzae</i> . <i>Journal of Clinical Microbiology</i> , <b>2002</b> , 40, 3269-76	9.7	13
37	The Changing Role of the Clinical Microbiology Laboratory in Defining Resistance in Gram-negatives. <i>Infectious Disease Clinics of North America</i> , <b>2016</b> , 30, 323-345	6.5	12
36	Activity of nitazoxanide and tizoxanide against <i>Mycobacterium tuberculosis</i> in vitro and in whole blood culture. <i>Tuberculosis</i> , <b>2016</b> , 98, 92-6	2.6	11
35	Failure to Communicate: Transmission of Extensively Drug-Resistant bla OXA-237-Containing <i>Acinetobacter baumannii</i> -Multiple Facilities in Oregon, 2012-2014. <i>Infection Control and Hospital Epidemiology</i> , <b>2017</b> , 38, 1335-1341	2	11
34	Prevention of otitis media: role of pneumococcal conjugate vaccines in reducing incidence and antibiotic resistance. <i>Journal of Pediatrics</i> , <b>2002</b> , 141, 287-93	3.6	11
33	Release of complement regulatory proteins from ocular surface cells in infections. <i>Current Eye Research</i> , <b>2000</b> , 21, 856-66	2.9	11
32	Activity of HMR 3647 compared to those of six compounds against 235 strains of <i>Enterococcus faecalis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , <b>1999</b> , 43, 166-8	5.9	11
31	Synergy of amoxycillin combined with clavulanate and YTR 830 in experimental infections in mice. <i>Journal of Antimicrobial Chemotherapy</i> , <b>1986</b> , 18, 271-6	5.1	11
30	SISPA-Seq for rapid whole genome surveys of bacterial isolates. <i>Infection, Genetics and Evolution</i> , <b>2015</b> , 32, 191-8	4.5	10
29	A $\beta$ -Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli. <i>Journal of Medicinal Chemistry</i> , <b>2020</b> , 63, 5990-6002	8.3	10
28	Complete Genome Sequence of a <i>Parabacteroides distasonis</i> Strain (CavFT hAR46) Isolated from a Gut Wall-Cavitating Microlesion in a Patient with Severe Crohn's Disease. <i>Microbiology Resource Announcements</i> , <b>2019</b> , 8,	1.3	9
27	Association of Laboratory Methods, Colonization Density, and Age With Detection of <i>Streptococcus pneumoniae</i> in the Nasopharynx. <i>American Journal of Epidemiology</i> , <b>2019</b> , 188, 2110-2119	3.8	8
26	Antimicrobial activity and in vitro corneal epithelial toxicity of antimicrobial agents for gram-positive corneal pathogens. <i>Current Eye Research</i> , <b>1993</b> , 12, 603-8	2.9	8
25	ARGONAUT II Study of the Activity of Plazomicin against Carbapenemase-Producing <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , <b>2020</b> , 64,	5.9	8
24	A $\beta$ -Lactam siderophore antibiotic effective against multidrug-resistant <i>Pseudomonas aeruginosa</i> , <i>Klebsiella pneumoniae</i> , and <i>Acinetobacter</i> spp. <i>European Journal of Medicinal Chemistry</i> , <b>2021</b> , 220, 113436	6.8	8
23	Bacterial contamination and septic transfusion reaction rates associated with platelet components before and after introduction of primary culture: experience at a US Academic Medical Center 1991 through 2017. <i>Transfusion</i> , <b>2020</b> , 60, 974-985	2.9	7
22	AAI101, a Novel $\beta$ -Lactamase Inhibitor: Microbiological and Enzymatic Profiling. <i>Open Forum Infectious Diseases</i> , <b>2017</b> , 4, S375-S375	1	7

21	Mechanisms of resistance among respiratory tract pathogens. <i>Clinics in Laboratory Medicine</i> , <b>2004</b> , 24, 419-53	2.1	7
20	Emergence of Resistance to Colistin During the Treatment of Bloodstream Infection Caused by Carbapenemase-Producing. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, ofy054	1	7
19	Identification of occult <i>Fusobacterium nucleatum</i> central nervous system infection by use of PCR-electrospray ionization mass spectrometry. <i>Journal of Clinical Microbiology</i> , <b>2014</b> , 52, 3462-4	9.7	6
18	<i>Streptococcus pneumoniae</i> : Activity of Newer Agents Against Penicillin-Resistant Strains. <i>Current Infectious Disease Reports</i> , <b>1999</b> , 1, 13-21	3.9	6
17	Sulfamethoxazole susceptibility of <i>Mycobacterium tuberculosis</i> isolates from HIV-infected Ugandan adults with tuberculosis taking trimethoprim-sulfamethoxazole prophylaxis. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 5844-6	5.9	4
16	Clinfloxacin Antibacterial Activity. <i>Drugs</i> , <b>1999</b> , 58, 217-221	12.1	3
15	AbGRI4, a novel antibiotic resistance island in multiply antibiotic-resistant <i>Acinetobacter baumannii</i> clinical isolates. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2020</b> , 75, 2760-2768	5.1	3
14	A two-part phase 1 study to establish and compare the safety and local tolerability of two nasal formulations of XF-73 for decolonisation of <i>Staphylococcus aureus</i> : A previously investigated 0.5mg/g viscosified gel formulation versus a modified formulation. <i>Journal of Global Antimicrobial Resistance</i> , <b>2020</b> , 21, 171-180	3.4	3
13	Extended release amoxicillin/clavulanate: optimizing a product for respiratory infections based on pharmacodynamic principles. <i>Expert Review of Anti-Infective Therapy</i> , <b>2005</b> , 3, 353-60	5.5	2
12	Recent advances in rapid antimicrobial susceptibility testing systems. <i>Expert Review of Molecular Diagnostics</i> , <b>2021</b> , 21, 563-578	3.8	2
11	Prolonged Course of <i>Salmonella</i> Pelvic Osteomyelitis in an Immunocompetent African American Child: A Case Report and Review of the Literature. <i>Journal of Pediatric Infectious Diseases</i> , <b>2018</b> , 13, 084-088	8.4	1
10	Antianaerobic Activity of Gatifloxacin. <i>Drugs</i> , <b>1999</b> , 58, 113-116	12.1	1
9	Postantibiotic Effect of Levofloxacin Against <i>Pneumococci</i> . <i>Drugs</i> , <b>1999</b> , 58, 378-380	12.1	1
8	Detection of <i>mcr-1</i> gene in a clinical <i>Escherichia coli</i> strain in North Carolina: first report. <i>Journal of Global Antimicrobial Resistance</i> , <b>2021</b> , 25, 154-156	3.4	1
7	Accuracy of Direct Antimicrobial Susceptibility of Gram-Negative Bacteria From Positive Blood Cultures using MicroScan System and Value of Using Expert Rules for $\beta$ -Lactam Agents.. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2022</b> , aac0214821	5.9	0
6	Multicenter Evaluation of the Acuitas $\square$ AMR Gene Panel for Detection of an Extended Panel of Antimicrobial Resistance Genes among Bacterial Isolates.. <i>Journal of Clinical Microbiology</i> , <b>2022</b> , JCM0209821	9.7	0
5	Genomic heterogeneity underlies multidrug resistance in <i>Pseudomonas aeruginosa</i> : A population-level analysis beyond susceptibility testing.. <i>PLoS ONE</i> , <b>2022</b> , 17, e0265129	3.7	0
4	Levofloxacin and Clarithromycin Antipneumococcal Activity. <i>Drugs</i> , <b>1999</b> , 58, 366-368	12.1	

- 3 Antipneumococcal Activity of Gatifloxacin by Time-Kill Methodology. *Drugs*, **1999**, 58, 369-371 12.1
- 2 Antipneumococcal Activity of Gatifloxacin by Agar Dilution MIC. *Drugs*, **1999**, 58, 372-373 12.1
- 1 Imipenem/Relebactam Resistance in Clinical Isolates of Extensively Drug Resistant *Pseudomonas aeruginosa*: Inhibitor-Resistant  $\beta$ -Lactamases and Their Increasing Importance.. *Antimicrobial Agents and Chemotherapy*, **2022**, e0179021 5.9